Relmada Therapeutics, Inc. (RLMD) Investor Relations Documents

Relmada Therapeutics, Inc. (RLMD) investor relations documents from the company's IR site: 1 presentation, 35 press releases; latest deck 2026-05-12. Read in-app with summaries. First-party data.

Unlocking Life Changing Therapies: Relmada Therapeutics is developing NDV-01, a sustained-release gemcitabine/docetaxel formulation for non-muscle invasive bladder cancer (NMIBC).

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06Press releaseQ2 2026 Financial Results
2026-07-28Press releaseRelmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
2026-07-16Press releaseRelmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
2026-06-29Press releaseRelmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
2026-06-11Press releaseRelmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
2026-05-28Press releaseRelmada Therapeutics to Present at the Jefferies Global Healthcare Conference
2026-05-28Press releaseDownload PDF file_download
2026-05-12Press releaseRelmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-12PresentationUnlocking Life Changing Therapies
2026-05-12Press releaseDownload PDF file_download
2026-05-06Press releaseDownload PDF file_download
2026-05-05Press releaseRelmada Therapeutics to Present NDV-01 Abstracts at AUA2026
2026-05-05Press releaseDownload PDF file_download
2026-03-19Press releaseRelmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
2026-03-09Press releaseRelmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
2026-03-09Press releaseRelmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
2026-01-12Press releaseRelmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for
2025-03-27Press releaseRelmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
2025-03-26Press releaseRelmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
2024-11-07Press releaseRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-11-04Press releaseRelmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
2024-08-05Press releaseRelmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024
2024-06-30Press releaseRelmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
2024-05-08Press releaseRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
2024-03-19Press releaseRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
2023-11-08Press releaseRelmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
2023-08-08Press releaseRelmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
2023-05-11Press releaseRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
2023-03-23Press releaseRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
2022-11-10Press releaseRelmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
2022-08-11Press releaseRelmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
2022-05-05Press releaseRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
2022-03-23Press releaseRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
2021-11-11Press releaseRelmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
2021-08-10Press releaseRelmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results
2021-05-01Press releaseRelmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021

RLMD overview · RLMD earnings · RLMD financials · RLMD KPIs · RLMD ownership · RLMD peers · RLMD filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.